



Stephan Krähenbühl

Kontakt

Stephan Krähenbühl

Publikationen (7)

Schett A, Rothschild S, Curioni-Fontecedro A, Krähenbühl S, Früh M, Schmid S, Driessen C, Jörgler M. Predictive impact of antibiotics in patients with advanced non small-cell lung cancer receiving immune checkpoint inhibitors : Antibiotics immune checkpoint inhibitors in advanced NSCLC. *Cancer Chemother Pharmacol* 2019; 85:121-131.

Hoemme A, Driessen C, Früh M, Thürlimann B, Wälti T, von Kameke A, Lehner C, Strasser F, Krähenbühl S, Haschke M, Barth H, Jörgler M. Prognostic impact of polypharmacy and drug interactions in patients with advanced cancer. *Cancer Chemother Pharmacol* 2019; 83:763-774.

Parra-Guillen Z, Kloft C, Krähenbühl S, Gillessen Sommer S, Früh M, Pfister B, Winogradova D, Donzelli M, Haschke M, Berger P, Jörgler M. Role of Cytochrome P450 3A4 and 1A2 Phenotyping in Patients with Advanced Non-small-Cell Lung Cancer Receiving Erlotinib Treatment. *Basic Clin Pharmacol Toxicol* 2017; 121:309-315.

Caduff Good A, Nobel D, Krähenbühl S, Geisen C, Henz S. Randomised trial of a clinical dosing algorithm to start anticoagulation with phenprocoumon. *Swiss Med Wkly* 2013; 143:w13709.

Jörgler M, Ferreri A, Krähenbühl S, Schellens J, Cerny T, Zucca E, Huitema A. Dosing algorithm to target a predefined AUC in patients with primary central nervous system lymphoma receiving high dose methotrexate. *Br J Clin Pharmacol* 2012; 73:240-7.

Bodmer M, Sulz M, Stadlmann S, Droll A, Terracciano L, Krähenbühl S. Fatal liver failure in an adult patient with acute lymphoblastic leukemia following treatment with L-asparaginase. *Digestion* 2006; 74:28-32.

Egger S, Sawatzki M, Drewe J, Krähenbühl S. Life-threatening hemorrhage after dalteparin therapy in a patient with impaired renal function. *Pharmacotherapy* 2005; 25:881-5.

Projekte (0)

Keine Resultate gefunden.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch